Science Daily23m
The heart of the question: Who can get Medicare-covered weight loss medicine?
With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans ...
Gizmodo12d
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
Wegovy and Other New Weight Loss Drugs Actually Work—so What’s Next? Novo Nordisk’s data has yet to be vetted by ...
devdiscourse3h
Senator Sanders Secures Commitments to Expand Coverage for Diabetes and Weight-loss Drugs
U.S. Senator Bernie Sanders announced he obtained commitments from top pharmacy benefit managers to expand coverage for Novo Nordisk's diabetes and weight-loss drugs if their list prices are reduced.
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D
Ozempic was approved in the US in late 2017 for diabetes, but its powerful effect on weight loss led to significant off-label ...
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.